Abbott (ABT) announced clinical data from two presentations at AF Symposium in Boston that demonstrate the strong safety and efficacy of the company's minimally invasive therapies to treat people with atrial fibrillation. The results include 12-month findings that reinforce the long-term safety and performance of Volt Pulsed Field Ablation System. Positive results were also presented on TactiFlex Duo Ablation Catheter, Sensor Enabled, a dual-energy, focal ablation catheter engineered to allow physicians to tailor how they deliver AFib therapy.
The Volt PFA System secured FDA approval and CE Mark in Europe, last year. Commercial cases have begun in the U.S. and expansion in Europe continues.
In pre-market trading on NYSE, Abbott shares are up 0.60 percent to $109.75.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.